-
公开(公告)号:US20070290133A1
公开(公告)日:2007-12-20
申请号:US11100800
申请日:2005-04-06
申请人: Edward Reber , James Jewell , Kenneth Rohde , Edward Seabury , Larry Blackwood , Andrew Edwards , Kurt Derr
发明人: Edward Reber , James Jewell , Kenneth Rohde , Edward Seabury , Larry Blackwood , Andrew Edwards , Kurt Derr
CPC分类号: G01V5/0008 , G01V5/0069
摘要: A method of detecting explosives in a vehicle includes providing a first rack on one side of the vehicle, the rack including a neutron generator and a plurality of gamma ray detectors; providing a second rack on another side of the vehicle, the second rack including a neutron generator and a plurality of gamma ray detectors; providing a control system, remote from the first and second racks, coupled to the neutron generators and gamma ray detectors; using the control system, causing the neutron generators to generate neutrons; and performing gamma ray spectroscopy on spectra read by the gamma ray detectors to look for a signature indicative of presence of an explosive. Various apparatus and other methods are also provided.
摘要翻译: 一种在车辆中检测爆炸物的方法包括在车辆的一侧提供第一齿条,所述齿条包括中子发生器和多个伽马射线探测器; 在所述车辆的另一侧上提供第二机架,所述第二机架包括中子发生器和多个伽马射线探测器; 提供远离第一和第二机架的控制系统,耦合到中子发生器和伽马射线探测器; 使用控制系统,使中子发生器产生中子; 并对由γ射线检测器读取的光谱执行伽马射线光谱,以寻找指示爆炸物存在的签名。 还提供了各种装置和其他方法。
-
公开(公告)号:US20070063143A1
公开(公告)日:2007-03-22
申请号:US11231141
申请日:2005-09-19
申请人: Larry Blackwood , Andrew Edwards , James Jewell , Edward Reber , Edward Seabury
发明人: Larry Blackwood , Andrew Edwards , James Jewell , Edward Reber , Edward Seabury
IPC分类号: G01N23/222
CPC分类号: G01N23/222
摘要: A method for detecting an element is described and which includes the steps of providing a gamma-ray spectrum which has a region of interest which corresponds with a small amount of an element to be detected; providing nonparametric assumptions about a shape of the gamma-ray spectrum in the region of interest, and which would indicate the presence of the element to be detected; and applying a statistical test to the shape of the gamma-ray spectrum based upon the nonparametric assumptions to detect the small amount of the element to be detected.
摘要翻译: 描述了用于检测元件的方法,其包括以下步骤:提供具有与少量待检测元件对应的感兴趣区域的伽马射线谱; 提供关于感兴趣区域中的伽马射线谱的形状的非参数假设,并且其将指示待检测的元素的存在; 并且基于非参数假设对伽马射线谱的形状进行统计测试以检测待检测的元素的少量。
-
公开(公告)号:US20110207711A1
公开(公告)日:2011-08-25
申请号:US13057325
申请日:2009-07-27
申请人: Jason Katz , James Jewell , Joon Jung , Solomon Kattar , Yongquan Hou , Rachel MacCoss , Satoru Ito
发明人: Jason Katz , James Jewell , Joon Jung , Solomon Kattar , Yongquan Hou , Rachel MacCoss , Satoru Ito
IPC分类号: A61K31/397 , C07D471/04 , A61K31/437 , C07D403/14 , A61K31/496 , C07D413/14 , A61K31/5377 , C07D401/14 , A61K31/517 , A61K31/5386 , A61P35/00 , A61P25/28 , A61P19/02 , A61P3/10 , A61P1/00
CPC分类号: A61K45/06 , A61K31/535 , C07D471/04 , C07D519/00 , A61K2300/00
摘要: The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.
摘要翻译: 本发明涉及作为激酶PDK1的抑制剂的吡唑并吡啶和咪唑并吡啶,因此可用于治疗骨髓增生性疾病或癌症。 该化合物也可用作其它激酶如FGFR3,NTRK3,RP-S6K和WEE1的抑制剂。 此外,本发明化合物还选择性地抑制微管亲和调节激酶(MARK),因此可用于治疗或预防阿尔茨海默氏病。
-
公开(公告)号:US20060293358A1
公开(公告)日:2006-12-28
申请号:US11473273
申请日:2006-06-22
申请人: Christopher Dinsmore , Ana Gabarda Ortega , David Guerin , James Jewell , Jason Katz , Jongwon Lim , Michelle Machacek , Ryan Otte , Jonathan Young
发明人: Christopher Dinsmore , Ana Gabarda Ortega , David Guerin , James Jewell , Jason Katz , Jongwon Lim , Michelle Machacek , Ryan Otte , Jonathan Young
IPC分类号: A61K31/473 , C07D221/02
CPC分类号: C07D471/04 , C07D221/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07D487/04 , C07D491/10 , C07D491/113 , C07F7/1804
摘要: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
-
公开(公告)号:US08455477B2
公开(公告)日:2013-06-04
申请号:US13057325
申请日:2009-07-27
申请人: Jason Katz , James Jewell , Joon Jung , Solomon Kattar , Yongquan Hou , Rachel MacCoss , Satoru Ito
发明人: Jason Katz , James Jewell , Joon Jung , Solomon Kattar , Yongquan Hou , Rachel MacCoss , Satoru Ito
IPC分类号: A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/5377 , A61K31/397 , A61K31/505 , A61K31/495 , A61K31/496 , A61K31/50 , C07F7/02 , C07D487/02 , C07D413/14 , C07D401/02 , C07D401/14 , C07D221/20
CPC分类号: A61K45/06 , A61K31/535 , C07D471/04 , C07D519/00 , A61K2300/00
摘要: The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.
摘要翻译: 本发明涉及作为激酶PDK1的抑制剂的吡唑并吡啶和咪唑并吡啶,因此可用于治疗骨髓增生性疾病或癌症。 该化合物也可用作其它激酶如FGFR3,NTRK3,RP-S6K和WEE1的抑制剂。 此外,本发明化合物还选择性地抑制微管亲和调节激酶(MARK),因此可用于治疗或预防阿尔茨海默氏病。
-
公开(公告)号:US20060115425A1
公开(公告)日:2006-06-01
申请号:US10559228
申请日:2004-06-25
申请人: H. Donald Burns , Alex Chen , Raymond Gibson , Mark Goulet , William Hagmann , Terence Hamill , James Jewell , Linus Lin , Ping Liu , Andrey Peresypkin
发明人: H. Donald Burns , Alex Chen , Raymond Gibson , Mark Goulet , William Hagmann , Terence Hamill , James Jewell , Linus Lin , Ping Liu , Andrey Peresypkin
IPC分类号: A61K51/00 , C07D213/70
CPC分类号: C07D213/64 , A61K51/0406 , A61K51/0455 , A61K51/0459 , C07D239/34
摘要: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.
摘要翻译: 本发明涉及特定的放射性标记的大麻素-1(CB1)受体调节剂,以及使用这些调节剂用于哺乳动物,特别是人类中大麻素-1受体的标记和诊断成像的方法。 此外,还公开了可用于合成放射性标记的大麻素-1受体调节剂的中间体,以及合成放射性标记的大麻素-1受体调节剂的方法。 此外,描述了放射性标记的大麻素-1受体化合物的制剂。
-
公开(公告)号:US20050239828A1
公开(公告)日:2005-10-27
申请号:US10507864
申请日:2003-03-21
申请人: William Hagmann , Linus Lin , Shrenik Shah , Mark Goulet , James Jewell
发明人: William Hagmann , Linus Lin , Shrenik Shah , Mark Goulet , James Jewell
IPC分类号: C07D307/24 , A61K31/165 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/351 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4425 , A61K31/445 , A61K31/4545 , A61K31/5375 , A61P1/10 , A61P1/14 , A61P1/16 , A61P3/04 , A61P9/10 , A61P11/06 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/34 , A61P25/36 , A61P29/00 , A61P43/00 , C07C233/59 , C07C235/40 , C07C235/82 , C07C237/24 , C07C255/60 , C07C271/24 , C07C317/44 , C07D205/04 , C07D207/16 , C07D207/28 , C07D207/38 , C07D207/48 , C07D211/60 , C07D211/62 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/82 , C07D213/89 , C07D265/30 , C07D307/68 , C07D309/08 , C07D401/04 , C07D41/02
CPC分类号: C07D207/38 , C07C233/59 , C07C235/40 , C07C235/82 , C07C237/24 , C07C255/60 , C07C271/24 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D205/04 , C07D207/16 , C07D207/48 , C07D211/60 , C07D211/62 , C07D213/56 , C07D213/61 , C07D213/82 , C07D213/89 , C07D265/30 , C07D307/24 , C07D307/68 , C07D309/08 , C07D401/04
摘要: Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译: 结构式(I)的新型化合物是大麻素-1(CB1)受体的拮抗剂和/或反向激动剂,可用于治疗,预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病,记忆缺陷,认知障碍,偏头痛,神经病,包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症,脑血管意外的精神药物 ,头部创伤,焦虑障碍,压力,癫痫,帕金森病,运动障碍和精神分裂症。 这些化合物也可用于治疗药物滥用障碍,治疗肥胖或进食障碍,以及治疗哮喘,便秘,慢性肠假性梗阻和肝硬化。
-
公开(公告)号:US20050234061A1
公开(公告)日:2005-10-20
申请号:US11109076
申请日:2005-04-19
申请人: William Hagmann , Linus Lin , Shrenik Shah , Ravindra Guthikonda , Hongbo Qi , Linda Chang , Ping Liu , Helen Armstrong , James Jewell , Thomas Lanza
发明人: William Hagmann , Linus Lin , Shrenik Shah , Ravindra Guthikonda , Hongbo Qi , Linda Chang , Ping Liu , Helen Armstrong , James Jewell , Thomas Lanza
IPC分类号: A61K31/165 , A61K31/27 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/415 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/423 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4436 , A61K31/445 , A61K31/4453 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/5377 , A61K31/553 , A61P1/04 , A61P1/10 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/24 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/06 , A61P13/12 , A61P15/00 , A61P15/10 , A61P17/00 , A61P19/02 , A61P19/06 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/16 , A61P25/18 , C07C233/12 , C07C233/13 , C07C235/06 , C07C235/18 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C323/41 , C07D207/27 , C07D209/08 , C07D209/34 , C07D209/52 , C07D209/94 , C07D211/34 , C07D213/36 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/89 , C07D215/06 , C07D231/12 , C07D233/36 , C07D233/70 , C07D233/80 , C07D237/14 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D249/18 , C07D261/08 , C07D261/20 , C07D263/58 , C07D267/14 , C07D277/20 , C07D277/30 , C07D277/36 , C07D277/64 , C07D277/74 , C07D295/12 , C07D295/13 , C07D295/14 , C07D295/15 , C07D401/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07D513/04 , C07D521/00 , A61K31/502 , A61K31/401
CPC分类号: C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
-
-
-
-
-
-
-